Vol 14, No 2 (2018)
Review paper
Published online: 2018-04-26
BRAF — a new therapeutic target in colorectal cancer
DOI: 10.5603/OCP.2018.0013
Oncol Clin Pract 2018;14(2):86-95.
Abstract
The BRAF V600E mutation, already a well-established biomarker in the treatment of metastatic melanoma, has been extensively studied in patients with metastatic colorectal cancer (CRC) in recent years. It was revealed that this mutation occurs in about 10% of CRC patients. It has been proven to be a negative prognostic factor, although more recent studies indicate a complex association of this effect with the state of genes responsible for the repair of “mismatch” DNA damage. Although the predictive value of the BRAF V600E mutation for chemotherapy and targeted treatment remains the subject of controversy, the guidelines of international scientific societies highlight the need for a different approach to systemic treatment of patients in this population. Numerous treatment options are currently evaluated: from the intensification of the classic chemotherapy regimens administered in the first-line setting to the innovative combinations of targeted drugs aimed at eliminating the influence of BRAF V600E mutation on signal transduction pathways that are crucial for carcinogenesis. The following review is intended to bring this complex topic to the attention of oncologists who deal with the treatment of gastrointestinal cancer in clinical practice.
Keywords: colorectal cancerBRAFV600EFOLFOXIRI
References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–E386.
- Didkowska J, Wojciechowska U, Olasek P. “Nowotwory złośliwe w Polsce w 2015 roku Cancer in Poland in 2015, ” Cancer, 2017. [Online]. Available: http://onkologia.org.pl/raporty/. [Accessed: 02-Jan. 2018].
- Seymour MT, Maughan TS, Ledermann JA, et al. FOCUS Trial Investigators, National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582): 143–152.
- Stintzing S, Modest D, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. The Lancet Oncology. 2016; 17(10): 1426–1434.
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.
- Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6: 479–507.
- Rad R, Cadiñanos J, Rad L, et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell. 2013; 24(1): 15–29.
- Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011; 2(3): 232–260.
- Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14(8): 749–759.
- Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20): 5322–5330.
- Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016; 27(9): 1746–1753.
- Cremolini C, Di Bartolomeo M, Amatu A, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015; 26(10): 2092–2097.
- Jones JC, Renfro LA, Al-Shamsi HO, et al. BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23): 2624–2630.
- Clancy C, Burke JP, Kalady MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2013; 15(12): e711–e718.
- Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010; 21(12): 2396–2402.
- Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28(3): 466–474.
- Kadowaki S, Kakuta M, Takahashi S, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 2015; 21(4): 1275–1283.
- Seligmann JF, Fisher D, Smith CG, et al. Investigating the poor outcomes of BRAF -mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials . Annals of Oncology. 2016: mdw645.
- Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120(15): 2316–2324.
- Renaud S, Romain B, Falcoz PE, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015; 112(4): 720–728.
- Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015; 112(12): 1921–1928.
- Mori Y, Nagasaka T, Tanioka H, et al. P-346Ovarian metastasectomy in colorectal cancer may improve the clinical outcomes of patients with metastatic colorectal cancer regardless of BRAF or KRAS mutational profiles. Annals of Oncology. 2017; 28(suppl_3).
- Johnson B, Jin Z, Truty M, et al. Impact of Metastasectomy in the Multimodality Approach forBRAFV600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. The Oncologist. 2017; 23(1): 128–134.
- Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
- Lochhead P, Kuchiba A, Imamura Yu, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15): 1151–1156.
- Seppälä TT, Böhm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015; 112(12): 1966–1975.
- Nakaji Yu, Oki E, Nakanishi R, et al. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. J Cancer Res Clin Oncol. 2017; 143(1): 151–160.
- Taieb J, Le Malicot K, Shi Q, et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017; 109(5).
- Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012; 49(3): 151–157.
- Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14): 6063–6069.
- Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148(1): 77–87.e2.
- Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3): 164–171.
- Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35): 5705–5712.
- Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101(4): 715–721.
- Roock WDe, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology. 2010; 11(8): 753–762.
- Karapetis CS, Jonker D, Daneshmand M, et al. NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014; 20(3): 744–753.
- Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012; 30(15): 1755–1762.
- Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48(10): 1466–1475.
- Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7): 1209–1214.
- Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94(6): 798–805.
- Falcone A, Ricci S, Brunetti I, et al. Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25(13): 1670–1676.
- Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. The Lancet Oncology. 2010; 11(9): 845–852.
- Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014; 50(1): 57–63.
- Cremolini C, Loupakis F, Masi G, et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 2016; 27(5): 843–849.
- Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4032–4038.
- Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015; 373(8): 726–736.
- Gomez-Roca CA, Delord J, Robert C, et al. 535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY. Annals of Oncology. 2014; 25(suppl_4): iv182–iv183.
- Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387): 100–103.
- Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3): 227–235.
- Yaeger R, Cercek A, O'Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015; 21(6): 1313–1320.
- Desai J, Markman B, Ananda S, et al. “A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study., ” J. Clin. Oncol., May 2017, vol. 35, no. 15_suppl, p. (suppl.3557): 3557P.
- van Geel RM, Tabernero J, Elez E, et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic-Mutant Colorectal Cancer. Cancer Discov. 2017; 7(6): 610–619.
- Corcoran RB, André T, Yoshino T, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC). Annals of Oncology. 2016; 27(suppl_6).
- Kopetz S, McDonough S, Morris V, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Journal of Clinical Oncology. 2017; 35(4_suppl): 520–520.